Literature DB >> 3158386

Synthetic retinoids in dermatology.

E H Heller, N J Shiffman.   

Abstract

The potential of vitamin A, or retinol, in the treatment of a variety of skin diseases has long been recognized, but because of serious toxic effects this substance generally could not be used. The recent development and marketing of two relatively non-toxic synthetic analogues, which are known as retinoids, has made it possible to treat some of the diseases that are resistant to standard forms of therapy. Isotretinoin is very effective in cystic and conglobate acne, while etretinate is especially useful in the more severe forms of psoriasis. Good results have also been obtained in other disorders of keratinization. Vitamin A and its derivatives apparently have an antineoplastic effect as well and may come to be used in both the prevention and the treatment of epithelial cancer. In many of these diseases the retinoids act by enhancing the normal differentiation and proliferation of epidermal tissues, but the exact mechanisms are not well understood. Their influence on the intracellular polyamines that control the synthesis of nucleic acids and proteins may be an important factor. Although the retinoids have few serious systemic effects, they are teratogenic, and because they persist in the body their use in women of childbearing potential is limited.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158386      PMCID: PMC1345937     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  59 in total

1.  Mucous metaplasia and gap junctions in the vitamin A acid-treated skin tumor, keratoacanthoma.

Authors:  L Prutkin
Journal:  Cancer Res       Date:  1975-02       Impact factor: 12.701

2.  Use of 13-cis-retinoic acid in cystic acne.

Authors:  N Kanigsberg; J P DesGroseilliers
Journal:  Can Med Assoc J       Date:  1983-08-01       Impact factor: 8.262

3.  Accutane Roche: risk of teratogenic effects.

Authors:  D P Zarowny
Journal:  Can Med Assoc J       Date:  1984-08-15       Impact factor: 8.262

4.  Etretinate treatment for psoriasis inhibits epidermal ornithine decarboxylase.

Authors:  N J Lowe; R Kaplan; J Breeding
Journal:  J Am Acad Dermatol       Date:  1982-04       Impact factor: 11.527

5.  Subcorneal pustular dermatosis (Sneddon-Wilkinson disease)--therapeutic problems.

Authors:  E Folkers; J Tafelkruyer
Journal:  Br J Dermatol       Date:  1978-06       Impact factor: 9.302

6.  Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid.

Authors:  J F Kessler; F L Meyskens; N Levine; P J Lynch; S E Jones
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

7.  Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate.

Authors:  O Rollman; A Vahlquist
Journal:  Br J Dermatol       Date:  1983-10       Impact factor: 9.302

8.  Retinoid therapy is associated with excess granulation tissue responses.

Authors:  J P Campbell; R C Grekin; C N Ellis; S S Matsuda-John; N A Swanson; J J Voorhees
Journal:  J Am Acad Dermatol       Date:  1983-11       Impact factor: 11.527

9.  Efficacy of etretinate (Tigason) in clearing and prevention of relapse of palmoplantar pustulosis.

Authors:  A Lassus; J Lauharanta; T Juvakoski; L Kanerva
Journal:  Dermatologica       Date:  1983

10.  Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359).

Authors:  A Lassus
Journal:  Br J Dermatol       Date:  1980-02       Impact factor: 9.302

View more
  2 in total

1.  Successful surgical management of keratoderma hereditaria mutilans.

Authors:  Jared J Liebman; Yuan Liu
Journal:  Hand (N Y)       Date:  2013-03

2.  What's the resolutive surgery for pseudo-ainhum in Vohwinkel syndrome? A case report and review of the literature.

Authors:  Giuseppe Rovere; Leonardo Stramazzo; Alessio Cioffi; Nicolò Galvano; Davide Pavan; Giuseppe Restuccia; Antonio D'Arienzo; Rodolfo Capanna; Giulio Maccauro; Michele D'Arienzo; Lawrence Camarda
Journal:  Orthop Rev (Pavia)       Date:  2021-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.